al-Refaie F N, Wonke B, Wickens D G, Aydinok Y, Fielding A, Hoffbrand A V
Department of Haematology, Royal Free Hospital, London.
J Clin Pathol. 1994 Jul;47(7):657-60. doi: 10.1136/jcp.47.7.657.
To determine the changes in serum zinc concentration and the extent of urinary zinc excretion in patients with iron overload receiving the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) or desferrioxamine (DFX), and to correlate these results with blood glucose concentration.
Serum zinc and ferritin concentrations, urinary zinc and iron excretion were regularly assayed in 39 patients and the glucose tolerance test (GTT) was performed in each patient. Patients were segregated according to their GTT into normal, diabetic, and those with an abnormal GTT. The mean of L1- or DFX associated urinary zinc excretion for each group was determined and compared with the other two groups and with normal value. L1 associated urinary zinc excretion was also compared with L1 dose, serum ferritin values, and urinary iron excretion.
Both DFX and L1 were associated with a significantly increased urinary zinc excretion (15.1 (7.3) mumol/24 hours, 11.1 (6.0) mumol/24 hours, respectively) compared with normal subjects. In patients receiving DFX this increase only occurred in patients with diabetes mellitus. Both diabetic and non-diabetic patients receiving L1 treatment excreted more zinc than normal. Diabetic patients receiving L1 or DFX excreted more zinc than non-diabetics receiving the same treatment. No correlation was found between urinary zinc excretion and L1 dose or patients' serum ferritin concentrations. In seven patients receiving long term L1 treatment a fall in serum zinc was observed from an initial 13.6 (1.6) mumol/l to a final 9.6 (0.8) mumol/l. In one patient this was associated with symptoms of dry skin and itchy skin patches requiring treatment with oral zinc sulphate.
In contrast to DFX, L1 treatment is associated with increased zinc loss. This, however, is modest and does not lead in most patients to subnormal serum zinc concentrations. In a few patients whose negative zinc balance may give rise to symptoms, zinc supplementation rapidly corrects the deficit.
测定接受口服铁螯合剂1,2 - 二甲基 - 3 - 羟基吡啶 - 4 - 酮(L1)或去铁胺(DFX)治疗的铁过载患者血清锌浓度的变化及尿锌排泄程度,并将这些结果与血糖浓度相关联。
对39例患者定期检测血清锌和铁蛋白浓度、尿锌和铁排泄量,并对每位患者进行葡萄糖耐量试验(GTT)。根据GTT结果将患者分为正常、糖尿病和GTT异常三组。确定每组L1或DFX相关的尿锌排泄平均值,并与其他两组及正常值进行比较。还比较了L1相关的尿锌排泄与L1剂量、血清铁蛋白值及尿铁排泄量。
与正常受试者相比,DFX和L1均与尿锌排泄显著增加有关(分别为15.1(7.3)μmol/24小时和11.1(6.0)μmol/24小时)。接受DFX治疗的患者中,这种增加仅发生在糖尿病患者中。接受L1治疗的糖尿病和非糖尿病患者排泄的锌均比正常患者多。接受L1或DFX治疗的糖尿病患者比接受相同治疗的非糖尿病患者排泄更多的锌。未发现尿锌排泄与L1剂量或患者血清铁蛋白浓度之间存在相关性。在7例接受长期L1治疗的患者中,观察到血清锌从初始的13.6(1.6)μmol/L降至最终的9.6(0.8)μmol/L。其中1例患者出现皮肤干燥和皮肤瘙痒斑块症状,需要口服硫酸锌治疗。
与DFX不同,L1治疗与锌流失增加有关。然而,这种增加幅度较小,大多数患者的血清锌浓度不会降至正常以下。在少数因锌负平衡可能出现症状的患者中,补充锌可迅速纠正缺乏。